MCM
SRPT icon

Marathon Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Marathon Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-41,575
Closed -$711K – 173
2025
Q2 		$711K Buy
+41,575
New +$1.77M 0.18% 79

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Marathon Capital Management's SRPT Position: Q3 2025 in Review

Marathon Capital Management sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 41,575 shares — an estimated $711K sold.

Marathon Capital Management first reported a position in SRPT in Q2 2025 and held it in 1 quarter. The position peaked at $711K in Q2 2025. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • Marathon Capital Management reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Marathon Capital Management sold 41,575 Sarepta Therapeutics shares in Q3 2025, an estimated $711K.
  • Marathon Capital Management first reported a position in Sarepta Therapeutics in Q2 2025 and held it in 1 quarter.
  • Marathon Capital Management's Sarepta Therapeutics position peaked at $711K in Q2 2025.
  • 319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Marathon Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.